CJC-1295 without DAC 5ml + IPA 5ml

Description

This vial combines CJC-1295 without DAC, a short-acting growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue receptor (GHS-R1a) agonist, supplied together for combination research protocols.

In laboratory research, the two compounds are studied for their complementary mechanisms: CJC-1295 without DAC acts on the GHRHR to stimulate the synthesis and release phase of growth hormone secretion, while Ipamorelin acts on a distinct receptor pathway to amplify the secretory pulse.

Researchers use dual-pathway blends of this kind to model synergistic activation of the somatotropic axis and to compare combined receptor engagement against single-agent administration in controlled experimental systems.

Because each peptide targets a separate receptor system, the combination is a useful research tool for dissecting the relative contribution of GHRH-receptor versus ghrelin-receptor signaling to overall growth hormone output.

This blend is intended strictly for laboratory research into peptide pharmacology and endocrine signaling pathways.